home

Breaking News

Redox Signs Licensing Agreement With OPKO Health, Inc.
On June 12, 2008, OPKO and Redox entered into an agreement whereby OPKO acquired the rights for all ophthalmic uses of Doxovir.

see OPKO Press Release

Redox Pharmaceutical Corporation has been granted approval from Health Canada to perform clinical studies on Herpes Labialis (cold sores).  Phase IB Clinical Trials (initial proof of safety and efficacy) have been successfully completed. A Phase II Clinical Trial on Herpes Labialis has been approved and has now been initiated.


©2008 Redox Pharmaceutical Corporation.
All right reserved.

Send us your site suggestions & service requests.

Site hosted by: Transbeam.com
Prophylactic
Sexually Transmitted Diseases (STDs)
Genital Herpes

Sexually transmitted Genital Herpes Simplex Viruses Type 1 (HSV -1) and Type 2 (HSV-2) infect an estimated 25% of adult Americans with 500,000 new cases appearing each year. After primary infection, the virus remains latent until recurrence. Recurrent outbreaks may be symptomatic or asymptomatic. Symptomatic episodes entail blisters on or around the genitals or rectum that burst leaving ulcers, which take weeks to heal. An individual infected by the HSV virus will carry the virus for life. The virus is transmitted to sexual partners during active herpes episodes. HSV-2 in the female genital tract can be the cause of potentially fatal infections of infants and newborns. HSV-2 infection appears to increase susceptibility to heterosexual spread of HIV infection.

Redox Pharmaceutical Corporation has preliminary demonstration that animals pre-treated with Doxovir-M™ were protected from Herpes type 2 infection.

Contact Us | Home

MEDICAL APPLICATIONS

Ocular Applications Adenovirus-derived Keratoconjunctivitis Herpetic Keratitis

Genital Applications Overview
HIV
Human Papillomavirus
Genital Herpes
Chlamydia

Dermal Application
Facial Herpes

Anti-Inflammatory Application
Non-Steroidal anti-inflammatory